Atlantic Therapeutics secures major investments from Borski Fund and the Western Development Commission to enhance its commercialization of the INNOVO device for treating stress urinary incontinence.
Target Information
Atlantic Therapeutics, based in Galway, Ireland, is a pioneering company focused on providing a non-invasive treatment for stress urinary incontinence through its flagship product, INNOVO. This innovative technology utilizes neuromuscular electrical stimulation (NMES) delivered via a wearable device to strengthen the pelvic floor muscles, addressing the underlying causes of stress urinary incontinence, a condition that affects one in three women globally.
The INNOVO device has received FDA approval and CE marking, enabling women to perform pelvic floor exercises discreetly at home. Recent clinical trials involving over 600 participants have demonstrated significant improvements in key symptoms, positioning INNOVO as a leading solution in the growing femtech market targeted at women's health.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Ireland
The healthcare technology industry in Ireland has been experiencing rapid growth, particularly within the femtech sector, which focuses on addressing women-centered healthcare
Similar Deals
First Analysis → TPN.health
2026
Borski Fund, Western Development Commission
invested in
Atlantic Therapeutics
in
in a Other VC deal